Compare Manchester United PLC (MANU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Merck & Co., Inc. — how do they compare? Manchester United PLC trades at $20.51 (market cap $3.51B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 100.1× Manchester United PLC's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Merck & Co., Inc. for 98 Days on average.
| MANU | MRK | |
|---|---|---|
Market Cap | $3.51B | $351.28B |
Volume | 412,769 | 7,969,665 |
Sector | Media | Health |
52-Week High | $24.19 | $156.43 |
52-Week Low | $15.20 | $82.49 |
Typical Hold Time | 109 Days | 98 Days |
Enterprise Value | $4.33B | $398.04B |
Dividend Yield | 1.26% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.32, up 0.35% with bearish technical signals despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $666.51M in 2025 but persistent net losses (-$33.02M) and negative margins. Analyst sentiment is divided with 40% buy ratings while technical indicators show selling pressure outweighing buying signals 10-5.
The stock presents a valuation opportunity with P/S of 3.9x below sports franchise peers, but faces execution risks from consistent losses and high debt. Upside depends on Champions League revenue conversion while downside risks include ongoing profitability challenges in the competitive Premier League landscape.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
